

Hiroshi Mitsumoto, M.D., D.Sc.

Publication (* as a senior author)

A. Original, Peer Reviewed Articles

1. Mitsumoto H, Conomy PJ, Regula G: Subdural hematoma: experience in a general hospital. *Cleveland_Clin Q* 1977; 44:95-100.
2. Mitsumoto H, Conomy JP, Regular G: Ophthalmologic aspects of subdural hematoma. *Cleveland Clin Q* 1977; 44:101-106.
3. Conomy JP, Regular G, Mitsumoto H: Age as a determinant in the neurology of subdural hematomas. *Trans Amer Neuro Assoc* 1976; 101-102.
4. Mitsumoto H: McArdle disease: phosphorylase activity in regenerating fibers. *Neurology* 1979; 29:258-262.
5. Streib EW, Wilbourn AJ, Mitsumoto H: Spontaneous electrical activity in polymyositis and dermatomyositis. *Muscle_Nerve*; 1979; 2:14-18.
6. Mitsumoto H, Wilbourn AJ, Goren H: Perineurioma as the cause of localized hypertrophic neuropathy. *Muscle_Nerve* 1980; 3:403-412.
7. Sivak E, Salanga V, Wilbourn AJ, Mitsumoto H: Diaphragmatic palsies in adult-onset acid maltase deficiency myopathy. *Ann_Neurol* 1981; 9:613-616.
8. Verghese P, Bradley WG, Mitsumoto H, Chad D: A blind controlled trial of ACTH and cerebral gangliosides and nerve regeneration in the rat. *Exp Neurol* 1982; 77:455-458.
9. Mitsumoto H, Bradley WG: The wobbler mouse: the murine motor neuron diseases: degeneration and regeneration of the lower motor neuron. *Brain* 1982; 105:811-834.
10. Mitsumoto H, Bradley WG, Aprille JR, Nemni R, Wray SH: Chronic progressive external ophthalmoplegia (CPEO): clinical, morphologic, and biochemical studies. *Neurology* 1983; 33:452-461.
11. Mitsumoto H: Axonal regeneration in murine motor neuron disease (the wobbler mouse). *Muscle Nerve* 1985; 8:44-51.
12. Mitsumoto H, Sliman RJ, Schafer IA, Sternick CS, Wilbourn AJ, Kaufman B, Horwitz SJ: Motor neuron disease and adult hexosaminidase-A deficiency in two families: Evidence for multisystem degeneration. *Ann Neurol* 1985; 17:378-385.
13. Mitsumoto H, Gambetti P: Impaired slow axonal transport in wobbler mouse motor neuron disease. *Ann_Neurol* 1986; 19:64-68.
14. Mitsumoto H, Salgado ED, Negroski D et al: Amyotrophic lateral sclerosis: Effects of acute intravenous and chronic subcutaneous administration of thyrotrophin-releasing hormone in controlled trials. *Neurology* 1986;36:152-159.
15. Mitsumoto H, Boggs AL: Vacuolated anterior horn cells in wobbler mouse motor neuron disease: Peripheral axons and regenerative capacity. *J Neuropathol Exp Neurol* 1987; 46:214-222.
16. Estes ML, Ewing-Wilson D, Chou SM, Mitsumoto H, Hanson MR, et al: Chloroquine neuromyotoxicity: A clinical and pathological prospective. *Amer J Med* 1987; 82:447-455.
17. Sivak ED, Ahmad M, Hanson MR, Mitsumoto H, Wilbourn AJ: The spectrum and management of respiratory insufficiency in adult-onset acid maltase deficiency. *Souther Med J* 1987; 80:205-208.
18. Calabrese LH, Mitsumoto H, Chou SM: Inclusion body myositis (IBM): Presenting as treatment-resistant polymyositis. *Arthr Rhem* 1987; 30:397-403.
19. *Kozachuk W, Mitsumoto H, Salanga V, Wilbur J: Effects of daily TRH administration in murine motor neuron disease (wobbler mouse). *J Neurol Sci* 1987; 78:253-260.
20. Mitsumoto H, Ferut AL, Kurahasi K, McQuarrie IG: Impairment of retrograde axonal transport in wobbler mouse motor neuron disease. *Muscle Nerve* 1990; 13:121-126.
21. Mitsumoto H, Bunge G, Andrish JT, DeBoer GE, Tetzlaff JE, Cruse RP: Fiber-type-specific caffeine sensitivities in normal human skinned muscle fibers. *Anesthesiology* 1990; 72:50-54.

22. Mitsumoto H, McQuarrie IG, Kurahashi K, Sunohara N: Histometric characteristics and regenerative capacity in wobbler mouse motor neuron disease. *Brain* 1990; 113:497-508.
23. Navon R, Kolodny EH, Mitsumoto H, Thomas GH, Proia RL: Ashkenazi Jewish and non-Jewish adult GM₂ gangliosidosis patients share a common genetic defect. *Am J Hum Genet* 1990; 46:817-821.
24. Sadig SA, Thomas FP, Kilidireas K, et al: The spectrum of neurological disease associated with anti-GM antibodies. *Neurology* 1990; 40:1067-1072.
25. Mitsumoto H, Schwartzman MJ, Estes ML, et al: Paroxysmal autonomic dysfunction and sudden death in stiff-man syndrome. *J Neurol* 1991; 238: 91-96.
26. Krieger C, Perry TL, Hansen S, Mitsumoto H: The wobbler mouse: amino acid contents in brain and spinal cord. *Brain Res* 1991; 551:142-144.
27. Krieger C, Perry TL, Hanson S, Mitsumoto H, Honore T: Excitatory amino acid receptor antagonists in murine motor neuron disease. *Can J Neurol Sci* 19:462-465, 1992.
28. Mitsumoto H, Kurahashi K, Jacob JM, McQuarrie IG: Retardation of fast axonal transport in wobbler mice. *Muscle Nerve* 1993; 16:542-547.
29. *Sawada K, Malchesky PS, Koo AP, Mitsumoto H: Myasthenia gravis therapy. A new immunoadsorbent technique can eliminate acetylcholine receptor antibodies. *Cleveland Clin J Med* 1993; 60: 60-64.
30. Krieger C, Lai R, Mitsumoto H, Shaw C: The wobbler mouse: quantitative autoradiography of glutamatergic ligand binding sites in spinal cord. *Neurodegeneration* 1993; 2:9-17.
31. *Ikeda K, Mitsumoto, H: In vivo and in vitro muscle tensions in wobbler mouse motor neuron disease. *Muscle Nerve*, 1993; 16: 979-981.
32. Hirano M, Silbestrì G, Blake DM (Mitsumoto H, one of 15 authors): Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE): clinical biochemical, and genetic features of an autosomal recessive mitochondrial disorder. *Neurology* 1994;44:721-7.
33. Mitsumoto H, Ikeda K, Holmlund TH, Greene T, Cedarbaum JM, Wong V, Lindsay RM: The effects of ciliary neurotrophic factor on motor dysfunction in wobbler mouse motor neuron disease. *Ann Neurol* 1994;36:142-8.
34. Mitsumoto H, Ikeda K, Klinkosz B, Cedarbaum JM, Wong V, Lindsay RM: Arrest of motor neuron disease in wobbler mice cotreated with CNTF and BDNF. *Science* 1994;265:1107-10.
35. *Ikeda K, Wong V, Holmlund TH, Greene T, Cedarbaum JM, Lindsay RM, Mitsumoto H: Histometric effects of ciliary neurotrophic factor in wobbler mouse motor neuron disease. *Ann Neurol* 1995;47:47-54.
36. Grob D, Simpson D, Mitsumoto H, et al.: Treatment of myasthenia gravis by immunoadsorption of plasma. *Neurology* 1995;45:338-344.
37. *Ikeda K, Klinkosz B, Greene T, Cedarbaum JM, Wong V, Lindsay RM, Mitsumoto H: Effects of brain-derived neurotrophic factor (BDNF) on motor dysfunction in wobbler mouse motor neuron disease. *Ann Neurol* 1995; 37:505-511.
38. Sato N, Brum JM, Mitsumoto H, DeBoer GE: Effect of cocaine on the contracture response to 1% halothane in patients undergoing diagnostic muscle biopsy for malignant hyperthermia. *Can J Anaesth* 1995; 42:158-62.
39. Den H-X, Tainer JA, Mitsumoto H, et al.: Two novel SOD 1 mutation in patients with familial amyotrophic lateral sclerosis. *Hum Molec Genet* 1995;4:113-116.
40. The ALS CNTF Treatment Study (ACTS) Phase I-II Study Group: The pharmacokinetics of subcutaneously administered recombinant human ciliary neurotrophic factor (rHCNTF) in patients with amyotrophic lateral sclerosis: relation to parameters of the acute-phase response. *Clin Neuropharmacol* 1995; 18:500-514.
41. The ALS CNTF Treatment Study (ACTS) Phase I-II Study Group: A phase I study of human ciliary neurotrophic factor (rHCNTF) in patients with amyotrophic lateral sclerosis. *Clin Neuropharmacol* 1995; 6:515-532.
42. Mitsumoto H, Saito T: Treatment trials in ALS. *Prog Br Res (Tokyo)* 1996; 40:132-144.

43. The ALS CNTF Treatment Study (ACTS) Phase I-II Study Group. The amyotrophic lateral sclerosis functional rating scale. Assessment of activities of daily living in patients with amyotrophic lateral sclerosis. *Arch Neurol* 1996;53:141-147.
44. The ALS CNTF Treatment Study (ACTS) Phase III Study Group. A double-blind placebo-controlled trial of subcutaneous recombinant human ciliary neurotrophic factor (rHCNTF) in amyotrophic lateral sclerosis. *Neurology* 1996; 46:1244-1249.
45. Mitsumoto H, Olney, RK: Drug combination treatment in patients with ALS: current status and future direction. *Neurology* 1996;47 (Suppl 2): S103-107.
46. Zu JS, Deng H-X, Lo, TP, Mitsumoto H, et al.: Exon 5 encoded domain is not required for the toxic function of mutant SOD1 but essential for the dismutase activity: identification and characterization of two new SOD1 mutations associated with familial amyotrophic lateral sclerosis. *Neurogenetics* 1997; 1:65-71.
47. Mitsumoto H, Kumar S, Levin KH, Tan M, Desai RG: Intravenous immunoglobulin treatment for amyotrophic lateral sclerosis. *Indian J Hematol Blood Transf* 1997;15:14-17.
48. *Aboussaouan LS, Khan SU, Meeker DP, Stelmack K, Mitsumoto H: The effect of non-invasive positive pressure ventilation on survival in amyotrophic lateral sclerosis. *Ann Int Med* 1997; 127: 450-453.
49. *Krivickas LS, Shockley L, Mitsumoto H: Home care of patients with amyotrophic lateral sclerosis (ALS). *J Neurol Sci* 1997; 152 (Suppl. 1): S82-89.
50. *Ishiyama T, Pioro EP, Klinkosz B, Mitsumoto H: Genetic transfer of the wobbler gene to C57/6J x NZB hybrid stock: natural history and response to CNTF and BDNF cotreatment. *J Exp Neurol* 1997; 148:247-255.
51. Mitsumoto H, Shockley L: Amyotrophic lateral sclerosis: continuum of care from diagnosis through hospice. *Home HealthCare Consultant* 1998;5:20-29.
52. *Pioro EP, Wang Y, Moore JK, Ng TC, Trapp BD, Klinkosz, Mitsumoto H: Neuronal pathology in the wobbler mouse brain revealed by in vivo proton magnetic resonance spectroscopy and immunocytochemistry. *NeuroReport* 1998; 9:3041-3046.
53. *Dal Bello-Haas V, Kloos AD, Mitsumoto H: Physical therapy for a patient through six stages of amyotrophic lateral sclerosis. *Physical Therapy* 1998;78:1312-1324.
54. *Pioro EP, Major T, Mitsumoto H, Ng T: Short TE 1H-MRSI of medulla in ALS: *In vivo* evidence of neurodegeneration and excess glutamate+glutamine. *Neurology* 1999; 53: 71-79.
55. Miller RG, Rosenber JA, Gelinas DF, Mitsumoto H, et al, and the ALS practice Parameters Task Force. Practice parameter: an evidence-based review. *Neurology* 1999; 52:1311-1323.
56. BDNF Study Group (Phase III). A controlled trial of recombinant methynil human BDNF in ALS. *Neurology* 1999; 52:1427-1433.
57. Esposito SJ, Mitsumoto H, Shanks M. Use of palatal lift and palatal augmentation prostheses to improve dysarthria in patients with amyotrophic lateral sclerosis: A cases series. *J Prosthet Dent* 2000; 83:90-98.
58. Miller RG, Anderson FA, Bradley WG, Mitsumoto H, Munsat TL, Ringel SP, and the ALS C.A.R.E. Study Group. The ALS patient care database. Goals, design, and early results. *Neurology* 2000; 54:53-57.
59. *Tsuzaka K, Ishiyama,T, Pioro EP, Mitsumoto H. Role of Brain-Derived Neurotrophic Factor in Wobbler Mouse Motor Neuron Disease. *Muscle Nerve* 2001; 24:474-480.
60. Mitsumoto H, DelBene M. Improving the quality of life for people with ALS: The challenge ahead. *ALS* 2000; 1:329-336.
61. *Dal Bello-Haas V, Andrews-Hinders D, Bocian J, Mascha E, Wheeler T, Mitsumoto H. Spiritual well-being of the individual with ALS. *ALS* 2000; 1:337-341.
62. Hentati A, Deng H-X, Zhai H, et al (13th of 18 authors). Novel mutations in spastin gene and absence of correlation with age at onset of symptoms. *Neurology* 2000; 55:1388-1390.

63. Aboussouan LS, Khan SU, Arroliga AC, Banerjee M, Mitsumoto H. Effect of noninvasive positive-pressure ventilation on pulmonary function, respiratory muscle strength and arterial blood gases in amyotrophic lateral sclerosis. *Muscle Nerve* 2001;24:403-409.
64. Mitsumoto H, Klinkosz B, Pioro EP, Tsuzaka K, Ishiyama T, O'Leary RM, Pennica D. The effects of cardiostrophin-1 (CT-1) in a mouse motor neuron disease. *Muscle Nerve* 2001; 24:769-777..
65. *Dal Bello-Haas V, Andrews-Hinders D, Balsdon Richer C, Blakely-Adams C, Hanson J, Hammel J, Kelly D, Kloos, A, Pioro EP, Powazki RD, Wheeler T, Mitsumoto H. Development, analysis, refinement, and utility of an interdisciplinary ALS 2001; 2:39-46.
66. Sivak ED, Shefner JM, Mitsumoto H, Taft IM. The use of non-invasive positive pressure ventilation (NIPPV) in ALS patients. A need for improved determination of intervention timing. *ALS* 2001;2: 139-146.
67. *Albert SM, Murphy PL, Del Bene M, Rowland LP, Mitsumoto H. Incidence and predictors of PEG placement in ALS/MND. *J Neurol Sci* 2001;191:115-120.
68. *Ishiyama T, Ogo H, Wong V, Klinkosz B, Nogushi, Nakayama C, Mitsumoto H. Methionine-free brain-derived neurotrophic factor in wobbler mouse motor neuron disease: dose-related effects and comparison with the methionyl form. *Brain Research* 2002; 944: 195-199.
69. Mitsumoto H. Caregiver assessment: summary. *ALS and Other MND 2002 (Suppl 1): S31-34.*
70. Mitsumoto H. Biochemical markers: con. *Amyotroph Lateral Scler Other Motor Neuron Disord* 2002; 3(Suppl 1): S83.
71. *Naini A, Musumeci O, Hayes L, Pallotti F, Del Bene M, Mitsumoto H. Identification of a novel mutation in Cu/Zn superoxide dismutase gene associated with familial amyotrophic lateral sclerosis *J Neurol Sci.* 2002;198:17-9.
72. Mitsumoto H, Brandis M, Del Bene ML. Ten most commonly asked questions about amyotrophic lateral sclerosis. *Neurologist* 2002;8:319-22.
73. Chan S, Kaufmann P, Shungu DC, Mitsumoto H. Amyotrophic lateral sclerosis and primary lateral sclerosis: evidence-based diagnostic evaluation of the upper motor neuron. *Neuroimag Clin N Am* 2003; 13:307-326.
74. Horner RD, Makins KG, Feussner JR, Grambow SC, Hoo-lindquist J, Harati Y, Mitsumoto H, et al. Occurrence of amyotrophic lateral sclerosis among Gulf War veterans. *Neurology* 2003;61:742-749.
75. Parton M, Mitsumoto H, Leigh P. Amino acids for amyotrophic lateral sclerosis / motor neuron disease. *Cochrane Database Syst Rev* 2003; 4:CD003457.
76. Mitsumoto H, Davidson M, Moore DH, et al. Percutaneous endoscopic gastrostomy (PEG) in patients with ALS and bulbar dysfunction. *ALS Other MND* 2003; 4: 177-185.
77. *Kloos AD, Dal Bello-Haas V, Thome R, Cassidy J, Lewis L, Cusma T, Mitsumoto H. Interrater and intrarater reliability of the Tinetti balance test for individuals with amyotrophic lateral sclerosis. *J Neurol Phys Ther* 2004; 28:12-19.
78. * Kaufmann P, Pullman SL, Shungu DC, et al, and H. Mitsumoto. Objective Tests for Upper Motor Neuron Involvement in Amyotrophic Lateral Sclerosis (ALS). *Neurology* 2004; 62:1753-1757.
79. Leung CL, He CZ, Kaufmann P, Chin SS, Naini A, Lien RK, Mitsumoto H, Hays AP. A pathogenic peripherin gene mutation in a patient with amyotrophic lateral sclerosis. *Brain Pathol* 2004;14; 290-296.
80. Shefner JM, Cudkowicz ME, Schoenfeld D, Conrad T, Taft J, Chilton M, Urbinelli L, Qureshi M, Zhang H, Pestronk A, Caress J, Donofrio P, Sorenson E, Bradley W, Lomen-Hoerth C, Pioro E, Reznia K, Ross M, Pascuzzi R, Heiman-Patterson T, Tandan R, Mitsumoto H, Rothstein J, Smith-Palmer T, MacDonald D, Burke D; NEALS Consortium. A clinical trial of creatine in ALS. *Neurology.* 2004; 63:1656-61.
81. *Kaufmann P, Levy G, Thompson JLP, DelBene ML, Battista V, Gordon P, Rowland LP, Levin B, Mitsumoto H. The ALSFRS_r predicts survival time in an ALS clinical population. *Neurology* 2005;64:38-43.

82. Scelsa SN, MacGowan DJ, Mitsumoto H, et al. A pilot, double-blind, placebo-controlled trial of indinavir in patients with ALS. *Neurology* 2005; 64:1298-300.
83. Albert SM, Rabkin JG, Del Bene ML, Tider T, O'Sullivan I, Rowland LP, Mitsumoto H. Wish to die in end-stage ALS. *Neurology* 2005;65:68-74 (With the editorial comments).
84. Rabkin J, Albert S, Del Bene M, O'Sullivan I, Tider T, Rowland LP, Mitsumoto H. Prevalence of depressive disorders and change over time in late-stage ALS. *Neurology* 2005;65: 62-67 (With the editorial comments).
85. Mitsumoto H, Bromberg M, Johnston W, et al. Promoting excellence in end-of-life care in ALS. *ALS and Other MND* 2005;6:145-154.
86. Li X, Rowland LP, Mitsumoto H, Przedborski S, Bird TD, Schellenberg GD, Peskind E, Johnson N, Siddique T, Mesulam MM, Weintraub S, Mastrianni JA. Prion protein codon 129 genotype prevalence is altered in primary progressive aphasia. *Ann Neurol.* 2005;58:858-864.
87. Gordon PH, Cheng B, Katz IB, Pinto M, Hays AP, Mitsumoto H, Rowland LP. The natural history of primary lateral sclerosis. *Neurology.* 2006;66:647-653.
88. Levy G, Kaufmann P, Buchsbaum R, Montes J, Barsdorf A, Arbing A, Battista V, Zhou X, Mitsumoto H, Levin B, Thompson JLP. A two-stage design for a phase II clinical trial of coenzyme Q10 in ALS. *Neurology* 2006;66:660-663.
89. Rippon GA, Scarmeas N, Gordon PH, Murphy PL, Albert SM, Mitsumoto H, Marder K, Rowland LP, Stern Y. An observational study of cognitive impairment in amyotrophic lateral sclerosis. *Arch Neurol.* 2006;63:345-52.
90. Gordon PH, Doorish C, Montes J, Mosley RL, Diamond B, MacArthur RB, Weimer LH, Kaufmann P, Hays AP, Rowland LP, Gendelman HE, Przedborski S, Mitsumoto H. Randomized controlled phase II trial of glatiramer acetate in amyotrophic lateral sclerosis. *Neurology* 2006;66:1117-1119.
91. Hays AP, Naini A, He CZ, Mitsumoto H, Rowland LP. Sporadic amyotrophic lateral sclerosis and breast cancer: Hyaline conglomerate inclusions lead to identification of SOD1 mutation. *J Neurol Sci* 2006;242:67-9.
92. Mitsumoto H, Floyd A, Tang MX, Kaufmann P, Battista V, Hristova A, Pullman SL. Transcranial magnetic stimulation for upper motor neuron involvement in amyotrophic lateral sclerosis (ALS). *Suppl Clin Neurophysiol.* 2006;59:327-32.
93. Rabkin JG, Albert SM, Tider T, Del Bene ML, O'Sullivan I, Rowland LP, Mitsumoto H. Predictors and course of elective long-term mechanical ventilation: A prospective study of ALS patients. *Amyotroph Lateral Scler.* 2006;7:86-95.
94. *Montes J, Levy G, Albert S, Kaufmann P, Buchsbaum R, Gordon PH, Mitsumoto H. Development and Evaluation of a Self-Administered Version of the ALSFRS-R. *Neurology* 2006;67:1294-6.
95. Kaufmann P, G Levy, J Montes, R Buchsbaum, MA Barsdorf, V Battista, R Arbing, P H Gordon, H Mitsumoto, BE Levin and JLP Thompson. Excellent inter-rater, intra-rater, and telephone-administered reliability of the ALSFRS-R in a multicenter clinical trial. *Amyotroph Lateral Scler* 2007;8:42-6..
96. Lange DJ, Lechtzin N, Davey C, David W, Heiman-Patterson T, Gelinas D, Becker B, Mitsumoto H; HFCWO Study Group. High-frequency chest wall oscillation in ALS: an exploratory randomized, controlled trial. *Neurology.* 2006;67(6):991-7.
97. Kaufmann P, Mitsumoto H; ALSRG Database Task Force Steering Committee; ALSRG Members. ALS Research Group (ALSRG): second meeting, a summary report. *Amyotroph Lateral Scler* 2006;7:252-5.
98. Whittle AJ, Ross OA, Naini A, Gordon P, Mitsumoto H, Dachsel JC, Stone JT, Wszolek ZK, Farrer MJ, Przedborski S. Pathogenic Lrrk2 substitutions and Amyotrophic lateral sclerosis. *J Neural Transm* 2007;114:327-9.
99. Lechtzin N, Lange DJ, Davey C, Becker B, Mitsumoto H. Measures of dyspnea in patients with amyotrophic lateral sclerosis. *Muscle Nerve* 2007;35:98-102.
100. Mitsumoto H, Uluğ AM, Pullman SL, et al. Quantitative Objective Markers for Upper and Lower Motor Neuron Dysfunction in Amyotrophic Lateral Sclerosis. *Neurology* 2007;17:1402-1410.

101. * Dal Bello-Haas V, Florence JM, Kloos AD, Scheirbecker J, Lopate G, Hayes SM, Pioro EP, Mitsumoto H. A Randomized Controlled Trial of Resistance Exercise in Individuals with ALS. *Neurology* 2007;68:2003-2007.
102. Naini A, Mehrazin M, Lu J, Gordon P, Mitsumoto H. Identification of a novel D109Y mutation in Cu/Zn superoxide dismutase (sod1) gene associated with amyotrophic lateral sclerosis. *J Neurol Sci* 2007;254:17-21.
103. Mitsumoto H, Rabkin JG. Palliative Care for Patients with amyotrophic lateral sclerosis. "Prepare for the worst and hope for the best." *JAMA* 2007;298: 207-216.
104. Mosley RL, Gordon PH, Hasiak CM, Van Wetering FJ, Mitsumoto H, Gendelman HE. Glatiramer acetate immunization induces specific antibody and cytokine responses in ALS patients. *Amyotroph Lateral Scler* 2007; 8:235-42.
105. Dunckley T, Huentelman MJ, Craig DW, Pearson JV, Szelinger S, Joshipura K, Halperin RF, Stamper C, Jensen KR, Letizia D, Hesterlee SE, Pestronk A, Levine T, Bertorini T, Graves MC, Mozaffar T, Jackson CE, Bosch P, McVey A, Dick A, Barohn R, Lomen-Hoerth C, Rosenfeld J, O'connor DT, Zhang K, Crook R, Ryberg H, Hutton M, Katz J, Simpson EP, Mitsumoto H, Bowser R, Miller RG, Appel SH, Stephan DA. Whole-Genome Analysis of Sporadic Amyotrophic Lateral Sclerosis. *N Engl J Med.* 2007;357:775-88.
106. Miller R, Bradley W, Cudkowicz M, Hubble J, Meininger V, Mitsumoto H, Moore D, Pohlmann H, Sauer D, Silani V, Strong M, Swash M, Vernotica E, TCH346 Study Group. Phase II/III randomized trial of TCH346 in patients with ALS. *Neurology* 2007;69:776-84.
107. Montes, J., Cheng, B., Diamond, B., Doorish, C., Mitsumoto, H. and Gordon, P. H. The Timed Up and Go test: Predicting falls in ALS. *Amyotroph Lat Scler* 2007; 8:292-295.
108. Radunovic A, Mitsumoto H, Leigh PN. Clinical care of patients with amyotrophic lateral sclerosis. *Lancet Neurol* 2007;6:913-25.
109. Gordon PH, Cheng B, Montes J, Doorish C, Albert SM, Mitsumoto H. Outcome measures for early phase clinical trials. *Amyotroph Lateral Scler* 2007;8:270-273.
110. Gordon PH, Wang Y, Doorish C, Lewis M, Battista V, Mitsumoto H, Marder K. A screening assessment of cognitive impairment in patients with ALS. *Amyotroph Lateral Scler.* 2007;8;362-365.
111. Gordon PG, Moore DH, Miller RG, Florence JM, Verheijde JL, Doorish C, Hilton JF, Spitalny GM, MacArthur RB, Mitsumoto H, et al. Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial. *Lancet Neurol* 2007; 6:1045-53.
112. Gwinn K, Corriveau RA, Mitsumoto H, et al. Amyotrophic Lateral Sclerosis: An Emerging Era of Collaborative Gene Discovery. *PloS ONE* 2007;1:e1254.
113. de Carvalho M, Dengler R, Eisen A, England JD, Kaji R, Kimura J, Mills K, Mitsumoto H, Nodera H, Shefner J, Swash M. Electrodiagnostic criteria for diagnosis of ALS. Consensus of an International Symposium sponsored by IFCN, December 3-5 2006, Awaji-shima, Japan. *Clin Neurophysiol* 2008;119:493-503.
114. Mitsumoto H, Santella RM, Liu X, Bogdanov M, Zipprich J, Wu H-C, Mahata J, Kilty M, Bednarz K, Bell D, Gordon PH, Hornig M, Mehrazin M, Naini A, M. Beal MF, Factor-Litvak P. Oxidative Stress Biomarkers in Sporadic ALS. *Amyotroph Lateral Scler* 2008; 9:177-83.
115. Chen A, Montes J, Mitsumoto H. The Role of Exercise in Amyotrophic Lateral Sclerosis. *Phys Med Rehabil Clin N Am.* 2008;19:545-557.
116. Gordon PH, Cheung YK, Levin B, et al (Mitsumoto H, 14/29 authors). A novel, efficient, randomized selection trial comparing combinations of drug therapy for ALS. *Amyotroph Lateral Scler.* 2008; 9:212-22.
117. Dimos JT, Rodolfa KT, Niakan KK, Weisenthal LM, Mitsumoto H, Chung W, Croft GF, Saphier G, Leibel R, Goland R, Wichterle H, Henderson CE, Eggan K. Induced pluripotent stem cells generated from patients with ALS can be differentiated into motor neurons. *Science* 2008; 321:1218-21.

118. Rutherford NJ, Zhang YJ, Baker M, Gass JM, Finch NA, Xu YF, Stewart H, Kelley BJ, Kuntz K, Crook RJ, Sreedharan J, Vance C, Sorenson E, Lippa C, Bigio EH, Geschwind DH, Knopman DS, Mitumoto H, Petersen RC, Cashman NR, Hutton M, Shaw CE, Boylan KB, Boeve B, Graff-Radford NR, Wszolek ZK, Caselli RJ, Dickson DW, Mackenzie IR, Petrucelli L, Rademakers R. Novel mutations in TARDBP (TDP-43) in patients with familial amyotrophic lateral sclerosis. *PLoS Genet.* 2008;4:e1000193.

Case Reports

1. Mitumoto H, et al: A case of amyloidosis associated with schistosomiasis japonica (in Japanese). *J Med Soc Toho* 1972;19:702-706.
2. Nanba T, Mitumoto H, Hirata K, Miura S: Hyperosmolar nonketotic diabetic coma associated with multiple organ defects (in Japanese). *J Med Soc Toho* 1972;19:528-537.
3. Conomy JP, Ferguson JH, Brodkey JS, Mitumoto H: Spontaneous infarction in pituitary tumors: neurologic and therapeutic aspects. *Neurology* 1975; 25:580-587.
4. Boller F, Wright DG, Cavalieri R, Mitumoto H: Paroxysmal "nightmares": sequel of a stroke responsive to diphenylhydantoin. *Neurology* 1975; 25:1026-1028.
5. Mitumoto H, Breuer AC, Lederman RJ: Malignant lymphoma of the central nervous system: a case of primary spinal intramedullary involvement. *Cancer* 1980; 46:1258-1262.
6. Mitumoto H, Sweeney PJ: Oculomotor palsy from malignant lymphoma. *Cleveland Clin Q* 1980; 47:333-338.
7. Sweeney PJ, Hahn JF, McHenry MC, Mitumoto H: Mucormycosis presenting as positional nystagmus and hydrocephalus. *J Neurosurg* 1980; 52:270-272.
8. Furlan AJ, Henry CE, Sweeney PJ, Mitumoto H: Focal EEG abnormality in Heidenhain's variant of Jakob-Creutzfeldt disease. *Arch Neurol* 1981;38:312-314.
9. Mitumoto H, Adelman LS, Liu HC: A case of congenital Werdnig-Hoffmann disease with glial bundles in spinal roots. *Ann Neurol* 1982; 11:214-216.
10. Chad D, Mitumoto H, Adelman LS, Bradley WG: Conjugal motor neuron disease. *Neurology* 1982; 32:306-308.
11. Mitumoto H, Wilbourn A, Subramony SH: Generalized myokymia and gold therapy. *Arch Neurol* 1982; 39:449-450.
12. Subramony SH, Mitumoto H, Mishra SK: Motor neuropathy associated with a facilitating myasthenic syndrome. *Muscle Nerve* 1986; 9:64-68.
13. *Caldron PH, Wilbourn AJ, Bravo EE, Mitumoto H: Gold myokymia syndrome. A rare toxic manifestation of chrysotherapy. *Cleveland Clin J Med* 1987;54:225-228.
14. Kosmorsky GS, Meisler DM, Sheeler LA, Tomsak RL, Sweeney PJ, Mitumoto H, MacRae S: Familial ophthalmoplegia-plus syndrome with corneal endothelial disorder. *Neuro-ophthalmology* 1989; 9:271-277.
15. Mitumoto H, Levin KH, Wilbourn AJ, Chou SM: Hypertrophic posterior tibial nerve mononeuritis clinically presenting with painful legs and moving toes. *Muscle Nerve* 1990; 13:215-221.
16. *Schwartzman MJ, Mitumoto H, Shields RW, Estes ML, Meisler DM, Kosmorsky GS: Neurogenic muscle weakness in chronic progressive external ophthalmoplegia (CPEO). *Muscle Nerve* 1990; 13:1183-1184.
17. Mitumoto H, Estes ML, Wilbourn AJ, Culver JE: A case of perineurial cell hypertrophic mononeuropathy manifesting as carpal tunnel syndrome. *Muscle Nerve* 1992; 15:1364-1368.
18. Rogers LR, Borkowski GP, Albers JW, Levin KH, Barohn RJ, Mitumoto H: Obturator mononeuropathy caused by pelvic cancer: six cases. *Neurology* 1993;43:1489-92.
19. Kosmorsky GS, Mehta N, Mitumoto H, Prayson R: Intermittent esotropia associated with rippling muscle disease. *J Neuroophthal* 1996; 15:147-151.

20. *Dynes GJ, Schwimer CJ, Staugaitis SM, Doyle JJ, Hays AP, Mitsumoto H. Amyotrophic Lateral Sclerosis with Multiple Sclerosis: A Clinical and Pathological Report. *ALS* 2000; 1:349-353.
21. Gordon PH, Mitsumoto H, Hays AP. Amyotrophic lateral sclerosis. *Sci Aging Knowledge Environ* 2003;35:dn2.
22. Hays AP, Naini A, He CZ, Mitsumoto H, Rowland LP. Sporadic amyotrophic lateral sclerosis and breast cancer: Hyaline conglomerate inclusions lead to identification of SOD1 mutation. *J Neurol Sci* 2006;242:67-9.
23. Chew S, Khandji AG, Montes J, Mitsumoto H, Gordon PH. Olfactory ensheathing glia injections in Beijing: Misleading patients with ALS. *Amyotroph Lateral Scler* 2007;8:314-6.
24. Hirano M, Angelini C, Montagna P, Hays AP, Tanji K, Mitsumoto H, Gordon PH, Naini AB, DiMauro S, Rowland LP. Amyotrophic lateral sclerosis with ragged-red fibers. *Arch Neurol* 2008;65:403-406.

C. Reviews

1. Mitsumoto H, Hanson MR, Chad DA: Amyotrophic lateral sclerosis (ALS): Recent advances in pathogenesis and therapeutic trials. *Arch Neurol* 1988; 45:189-202.
2. Mitsumoto H: Clinical trials of thyrotropin-releasing hormone (TRH) in patients with amyotrophic lateral sclerosis (ALS) and in motor neuron disease of wobbler mice. *Internat Cong Series* 1988;769:295-300.
3. Mitsumoto H. Therapeutic trials in ALS, current and future. *Neurol Therapy (Tokyo)* 1993; 10:519-526.
4. Mitsumoto H, Wilbourn AJ: Causes and diagnoses of sensory neuropathies. A review. *J Clin Neurophysiol* 1994,11:553-567.
5. *Cohen B, Mitsumoto H: Neuropathy syndromes associated with antibodies against the peripheral nerve. *Lab Med* 1995; 26: 459-463.
6. *Pioro, EP, Mitsumoto H: Animal models of ALS. *Clin Neurosci* 1996; 3: 375-385.
7. Mitsumoto H: A review. Neurotrophic factor treatments. *Jap J Neuropsychopharmacol* 1996;18: 779-788.
8. Mitsumoto H: Diagnosis and progression of ALS. *Neurology* 1997; 48(Suppl 4): S2-S8.
9. Miller RG, Sufit R, Mitsumoto H, Gelinus DF, Brooks BR: ALS standard of care consensus. *Neurology* 1997; 48(Suppl 4): S33-S37.
10. *Tsuzaka K, Mitsumoto H: Recent progress in treatment with neurotrophic factors in patients with ALS. *Brain and Nerve_(Tokyo)* 1998;50:625-630.
11. Mitsumoto H: Pharmacotherapy in ALS. *Annual Review: Nervous System (Tokyo)* 1998;16:926-931.
12. Mitsumoto H, Tsuzaka K: Invited Review. Neurotrophic factors and neuromuscular diseases. Part I and Part II. *Muscle Nerve* 1999; 22: 983-999 (I) and 1000-1021 (II).
13. Mitsumoto H. BDNF Treatment in Amyotrophic Lateral Sclerosis. In Abe K (ed): *Molecular Mechanism and therapeutics of ALS*. International Congress Series 1221. Elsevier, Tokyo. 2001; 365-374.
14. Mitsumoto H. Clinical trials: present and future. *ALS* 2001; 2 (suppl 1):S10-S14.K
15. *Kaufmann P, Mitsumoto H. Amyotrophic lateral sclerosis: objective upper motor neuron markers. *Cur Neurol Neurosci Rep* 2002; 2:55-60.
16. Kamiski HJ, Richmonds CR, Kusner LL, Mitsumoto H. Differential susceptibility of the ocular motor system to disease. *Neurobiology of Eye Movements from molecules to behavior*. *Ann New York Acad Sci* 2002; 956:42-53.
17. *Dal Bello-Haas V, Del Bene M, Mitsumoto, H. End of Life: Challenges and Strategies for the Rehabilitation Professional. *Neurol Report* 2002; 26:174-183.
18. Mitsumoto H, Brandis M, Del Bene ML. Ten most commonly asked questions about amyotrophic lateral sclerosis. *Neurologist* 2002;8:319-22.

19. Przedborski S, Mitsumoto H, Rowland LP. Recent advances in amyotrophic lateral sclerosis. *Curr Neurol Neurosci Rep* 2003; 2:70-77.
20. Mitsumoto H. Current progress in ALS therapy: Status report. *Neurol Therap (Tokyo)* 2003; 20:541-549 (in Japanese with English abstract).
21. Mitsumoto H. The challenge in caring for patients with ALS at home in the United States. Transcription of the key note lecture (in Japanese) given in Tokyo, Feb. 2003. *Japanese Home Care Medicine* 2003; 5: 15-24.
22. Leigh PN, Swash M, Iwasaki Y, Ludolph A, Meininger V, Miller RG, Mitsumoto H, Shaw P, Tashiro K, Van Den Berg L. Amyotrophic lateral sclerosis: a consensus viewpoint on designing and implementing a clinical trial. *Amyotroph Lateral Scler Other Motor Neuron Disord.* 2004;5:84-98.
23. Mitsumoto H, Gordon P, Kaufmann P, Gooch C, Przedborski S, Rowland P. Randomized control trials in ALS: lessons learned. *Amyotroph Lateral Scler and Other Motor Neuron Disease* 2004; 5(suppl 1): 1-13.
24. Mitsumoto H. Management and care for patients with ALS. *Clinic Neurol* 2006; 46:828-831 (Japanese).
25. Mitsumoto H. A strategy to develop effective ALS therapy. *Brain Nerve* 2007; 59:383-391 (Japanese).
26. Mitsumoto H. Current Status and Future Prospect of ALS Therapy. *Clin Neurosc* 2008;26:325-329 (Japanese).

D. Monographs and Editing

1. Mitsumoto H, Chad D, Piro EP: Monograph. Amyotrophic lateral sclerosis. *Contemporary Neurology Series* 49. Philadelphia: F. A. Davis. 1997: 1-480.
2. Mitsumoto H. and Norris FT, Jr. Amyotrophic Lateral Sclerosis: Comprehensive Management and Treatment. Demos Publisher, New York, 1994.
3. Gutmann L, Mitsumoto H (Supplement Editors): *Advances in Amyotrophic Lateral Sclerosis.* *Neurology* 47, 1996.
4. Mitsumoto H: (Section Editor): *Continuum. Motor Neuron Disease.* American Academy of Neurology. Baltimore: Williams & Wilkins, 1997.
5. Mitsumoto H, Munsat TL (Eds). *Amyotrophic Lateral Sclerosis. Patient and Family Guide to Management and Care.* Demos, New York. 2001.
6. Anonymous (Mitsumoto H. Chair). *Completing the Continuum of ALS Care: A Consensus Document. Promoting Excellence in End-of-life Care.* The Robert Wood Johnson Foundation. 2004.
7. Mitsumoto H, Przedborski S (Suppl Eds). *ALS Clinical Trials – The Challenge of the Next Century.* *Amyotroph Lateral Scler and Other Motor Neuron Disease* 2004; 5 (suppl 1): 1-143.
8. Mitsumoto H, Przedborski S, Gordon P (Eds). *Amyotrophic Lateral Sclerosis. Current Science and Approaches to Therapy.* Taylor & Francis Group, New York, 2006.

E. Book Chapters

1. Mitsumoto H, Munsat TL: Neuromuscular diseases and spinal cord and root problems. In: *Fundamentals of Internal Medicine*, edited by D. Kaye, and L. Rose, Mosby Company, St. Louis, 1982, pp. 1169-1178.
2. Mitsumoto H, Bradley WG: Axonal pathology in the murine motor neuron disease. In: *Current Trends in Neuroscience Vol. 3*, edited by M. Adachi, A. Hirano, and G. Aronson, Igaku-Shoin Med. Publisher, Tokyo-New York, 1985, pp 126-149.
3. Mitsumoto H, Bradley WG: Chapter 1. Development and structure of nerves. In: Vinken and Bruyn (eds): *Neuropathies. Handbook of Clinical Neurology*, Vol. 7. North-Holland, Amsterdam, 1987, pp 1-22.

4. Mitsumoto H: Motor Neuron Disease. In: Current Clinical Practice. F.H. Messerli: (ed). W. B. Saunders 1987, pp 700-702.
5. Mitsumoto H: Study of motor neuron disease. An approach with an animal model (the wobbler mouse) In: Contributions to Contemporary Neurology: A Tribute to Joseph M. Foley, M.D. Daroff RB, Conomy JP (eds). Butterworth, Stoneham, 1988, pp. 127-142.
6. Mitsumoto H: Therapeutic trials in ALS (Discussion). T. Tsubaki and Y. Yase (Eds.). International Conference of Amyotrophic Lateral Sclerosis. Simul International. Osaka, 1988, pp. 117-138.
7. Mitsumoto H, Munsat TL: Problems of Nerve and Muscle. In: Internal Medicine for Dentistry 2nd edition, edited by D. Kaye and L. Kose. Mosby Company, St. Louis. 1990, pp.746-755.
8. Bosch EP, Mitsumoto H: Disorders of peripheral nerves. In: Neurology in Clinical Practice. Bradley WG, Daroff RB, Fenichel GM, Marsden CD (eds). Butterworth Publishers. 1990, pp.1719-1792.
9. Breuer AC, Mitsumoto H, Atkinson MB: Axonal transport abnormalities in motor neuron disease: A possible role of endogenous or exogenous chemical agents. In: Neurotoxicology and Epidemiology on Motor Neuron Disease. F.C. Rose (ed). Demos, New York. 1991, pp. 243-246.
10. Mitsumoto H. Amyotrophic lateral sclerosis (ALS). A study of an animal model (The Wobbler Mouse). Proceedings of the XIth International Congress of Neuropathology. The Japanese Society of Neuropathology. Kyoto. 1991, pp. 601-604.
11. *Cwik V, Mitsumoto H: Post-polio syndrome. In: Handbook of Amyotrophic Lateral Sclerosis. R.A. Smith (ed). Marcel-Dekker, New York. 1992, pp.77-91.
12. Mitsumoto H, Lopez CL: Peripheral Neuropathy. In Conn's Current Therapy. R.E. Rakel (ed). Saunders, Philadelphia. 1992, pp.886-896.
13. Mitsumoto H, Ikeda K, Wong V, Cedarbaum JM, Lindsay RM. Wobbler Mouse Motor Neuron Disease and Neurotrophic Factors. The Forbes H. Norris Memorial Volume, Smith-Gordon, London, 1994, pp. 211-223.
14. Mitsumoto H. Classification and clinical features of ALS. In Mitsumoto H, Norris FT, Jr (eds). Amyotrophic Lateral Sclerosis: Comprehensive Management and Treatment. Demos Publisher, New York, 1994; pp. 1-20.
15. Mitsumoto, H: Motor Neuron Disease: The Path to Clinical Trials. Syllabus for the American Academy of Neurology Postgraduate Course. In M. Brooke (Director): Recent Advances in Neuromuscular Diseases. Published by AAN, New York, 1993.
16. Mitsumoto, H: New therapeutic approaches. In: Motor Neuron Disease (Amyotrophic Lateral Sclerosis). Leigh N., Swash M (eds). Springer-Verlag, London, 1995, pp. 419-441.
17. Mitsumoto, H, Wilbourn AJ: Spectrum of acquired sensory neuropathies: clinical, electrodiagnostic, and pathologic studies. In Asbury AK, Budka H, Sluga E (eds): Sensory neuropathies. Wien/New York; Spring-Verlag, 1995, pp. 91-104.
18. Bosch EP, Mitsumoto H: Disorders of peripheral nerves. In: Neurology in Clinical Practice. 2nd edition, Bradley WG, Daroff RB, Fenichel GM, Marsden CD (eds). Butterworth Publishers. 1995;1881-1952.
19. *King PH, Mitsumoto H: Neuropathology of Amyotrophic Lateral Sclerosis. In J. Belsh & P Schiffman (eds): ALS: Diagnosis and Management for the Clinician, Futura, New York, 1996, pp. 203-218.
20. Mitsumoto H, Piro, EP: Animal Models of Motor Neuron Disease. In Serratrice G, Munsat TL, eds: Pathogenesis and Treatment of Amyotrophic Lateral Sclerosis. Lippincott-Raven Publishers, Philadelphia. 1995, pp.73-87.
21. Mitsumoto H: A new approach for treatment of ALS (in Japanese). In: Tashiro K, Mizuno, Y, Kurihara T (eds): Modern Concept of Neurology. Igakushoin, Tokyo. 1995, pp. 146-152.
22. Mitsumoto H: Advances in ALS clinical trials. In Nakano I, Hirano A (eds): Amyotrophic Lateral Sclerosis. Amsterdam: Elsevier, 1996, pp. 374-384. Mitsumoto H: ALS: Hypotheses of pathogenesis and clinical trials. Excerpta Medica International Congress Series 1101 (Xth

- International Congress of EMG and Clinical Neurophysiology), Elsevier, Amsterdam. 1996, pp. 355-361.
23. Mitsumoto H (as an author): Introduction (pp8-9), Adult spinal muscular atrophy (pp33-40), Kennedy disease (pp 41-46), Benign focal amyotrophy (pp 111-115), Disorders of motor neurons manifested by hyperactivity (pp 121-128), Trends (pp 129), and Patient Management Problem (pp137-156). In: Continuum. Motor Neuron Disease (ed. Mitsumoto, H). Williams and Wilkins, Baltimore. 1997.
 24. Mitsumoto H: Amyotrophic lateral sclerosis. In: Adelman A, Smith B (eds): Encyclopedia of Neuroscience in CD-Rom. Elsevier, New York, 1998.
 25. H, Mitsumoto H. Muscle Physiology and Pathophysiology. Levin K, Lüder HO (eds). Comprehensive Clinical neurophysiology. W S Saunders, Philadelphia. 2000; 81-88.
 26. Cole B, Mitsumoto H. Amyotrophic Lateral Sclerosis. In 2000 Baker's Clinical Neurology on CD Rom (edited by Joynt R and Griggs RC). Lippincott, Williams & Wilkins, Baltimore, 2000 and 2002 (new edition).
 27. Murray B, Mitsumoto H. Drug therapy in Amyotrophic Lateral Sclerosis. In Pourmand R and Haratic Y (eds). Advances in Neurology. Vol 88. Neuromuscular Disorders. Philadelphia: Lippincott Williams & Wilkins. 2001; pp 63-82.
 28. Murray B, Mitsumoto H. Amyotrophic Lateral Sclerosis. In Katerji B, Kaminski H Preston D, Ruff R, Shapiro B (eds): Neuromuscular Disorders in Clinical Practice. Boston: Butterworth-Heimann. 2002, pp. 417-444.
 29. Mitsumoto H: Section Editor for Motor Neuron Diseases. In Brown WR, Bolton CP, Aminoff MJ (eds). Neuromuscular Function and Disease, Saunders, 2002; pp.1263-1326.
 30. Gooch CL, Mitsumoto H. Infectious, syndromic, and systemic disorders. In Brown WR, Bolton CP, Aminoff MJ (eds). Neuromuscular Function and Disease, Saunders, 2002; pp. 1281-1294.
 31. Murray B, Mitsumoto H. Drug therapy in amyotrophic lateral sclerosis. In Pourmand R and Harati Y (eds). Neuromuscular Disorders. Lippincott Williams and Wilkins. New York. Advances in Neurology 2002;88 63-82. .
 32. Mitsumoto H. Nutritional management for patients with amyotrophic lateral sclerosis. In Miller RG (ed). Continuum. Amyotrophic Lateral Sclerosis, AAN. 2002: 95-109.
 33. Murray B, Mitsumoto H. Disorders of Upper and Lower Motor Neuron Diseases (Chapter 78). In Bradley WG, Daroff RB, Fenichel GM, Jankovic J., Eds. Neurology in clinical Practice 4th Edition. 2004; 2223-2266.
 34. Rowland LP, Mitsumoto H, De Vivo DC. Hereditary and acquired motor neuron diseases. In Rowland LP (ed): Merritt's Neurology. 11th edition. Lippincott Williams and Wilkins. Baltimore, 2005; 861-869.
 35. Murray B, Mitsumoto H. The spectrum of motor neuron disorders. In Brown RH Jr, Swash M, Pasinelli P (eds). Amyotrophic Lateral Sclerosis. Informa, London, 2006;3-24.
 36. Gordon PH, Mitsumoto H. Symptomatic therapy and palliative aspects of clinical care. In Eisen AA, Shaw PJ (eds). Motor Neuron Disorders and Related Diseases. Handbook of Clinical neurology. 2007; 82:389-424.
 37. Murray B, Mitsumoto H. Disorders of Upper and Lower Motor Neuron Diseases (Chapter 78). In Bradley WG, Daroff RB, Fenichel GM, Jankovic J., Eds. Neurology in clinical Practice 5th Edition. 2008; 2183-2220.

F. Editorial

1. Mitsumoto H: Riluzole -- What is its impact in our treatment and understanding of amyotrophic lateral sclerosis? (Editorial) Ann Pharmacotherapy 1997; 31: 779-781.
2. Mitsumoto, H: Patient choices in ALS. Life-sustaining treatment versus palliative care? (Editorial) Neurology 1999; 53:248-249.

3. Mitsumoto H. GDNF is trophic for mouse motoneurons that express a mutant superoxide dismutase (SOD1) gene (Editorial). *Amyotroph Lateral Scler Other Motor Neuron Disord* 2000; 1:69-70.
4. Leigh PN, Mitsumoto H. MMT vs MVIC: Low-tech scores high? (Editorial). *Neurology* 2003;61: 1472-1473.
5. Levin BJ, Thompson G, Mitsumoto LH, Kaufmann P. Pentoxifylline in ALS: a double-blind, randomized, multicenter, placebo-controlled trial. *Neurology* 2006;66:1786-7; author reply 1786-7.

G. Letters and Others

1. Fantelli FJ, Mitsumoto H, Sebek BA: Multiple sclerosis and malabsorption (letter to editor). *Lancet* 1978; ii:1039-1040.
2. Mitsumoto H, et al: TRH and amyotrophic lateral sclerosis. Replies from the authors. *Neurology* 1987; 37:175-176.
3. Mitsumoto H, et al: Don't throw out the baby with the bath water. Reply from the authors. *Neurology* 1987; 37:544-545.
4. Mitsumoto H: Identify malignant hyperthermia susceptibility to avert life-threatening episodes. *Highlights from Medical Grand Rounds. Cleveland Clin J Med* 1989; 56:754-755.
5. *Ikeda K, Mitsumoto H, Tantar M, Dashefsky LH: Imaging in motor neuron disease (letter). *Neurology* 1994; 44:1186.
6. Aboussouan LS, Khan SU, Mitsumoto H: In reply to Positive-pressure ventilation in amyotrophic lateral sclerosis. *Ann Int Med* 1998; 128: 601-602.
7. Mitsumoto H. Clinical Highlights (Conference report): *Amyotroph Lat Sclerosis* 2007;8:119-120.